Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients

By Tan Xiang-Lin   Popanda Odilia   Ambrosone Christine   Kropp Silke   Helmbold Irmgard   Fournier Dietrich   Haase Wulf   Sautter-Bihl Marie   Wenz Frederik   Schmezer Peter   Chang-Claude Jenny  

Breast Cancer Research and Treatment, Vol. 97, Iss. 3, 2006-06 ,pp. : 255-262

Springer Publishing Company

Access to resources Recommend Favorite

TP53 Mutation is an Independent Prognostic Marker for Poor Outcome in Both Node-negative and Node-positive Breast Cancer

By Overgaard Jens   Yilmaz Mette   Guldberg Per   Hansen Lise Lotte   Alsner Jan  

Acta Oncologica, Vol. 39, Iss. 3, 2000-10 ,pp. : 327-333

Informa Healthcare

Access to resources Recommend Favorite

BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy

By Foedermayr Mathilde   Sebesta Miriam   Rudas Margaretha   Berghoff Anna   Promberger Regina   Preusser Matthias   Dubsky Peter   Fitzal Florian   Gnant Michael   Steger Guenther   Weltermann Ansgar   Zielinski Christoph   Zach Otto   Bartsch Rupert  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 4, 2014-04 ,pp. : 771-778

Springer Publishing Company

Access to resources Recommend Favorite

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation

By Groenendijk Floris   Taal Walter   Dubbink Hendrikus   Haarloo Cathleen   Kouwenhoven Mathilde   Bent Martin   Kros Johan   Dinjens Winand  

Journal of Neuro-Oncology, Vol. 101, Iss. 3, 2011-02 ,pp. : 405-417

Springer Publishing Company

Access to resources Recommend Favorite

The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer

By  

The Women's Oncology Review, Vol. 4, Iss. 2, 2004-06 ,pp. : 139-140

Informa Healthcare

Access to resources Recommend Favorite